Print

04/400-003-04

GENEVAX-HIV (APL 400-003), a Candidate DNA Vaccine: A Pilot Dose Escalation Study of GENEVAX-HIV Delivered Intramuscularly Using the Biojector 2000 in HIV Seronegative Volunteers

Trial Details:

I Completed
Wyeth-Lederle
APL 400-003 GENEVAX-HIV env,rev
APL 400-003 GENEVAX-HIV DNA
USA 18
NCT00002231
http://clinicaltrials.gov/ct2/show/NCT00002231